[{"_1":2,"_110":-5,"_111":-5},"loaderData",{"_3":4,"_26":27},"root",{"_5":6,"_17":10,"_18":19,"_20":21,"_22":10,"_23":-5,"_24":-5,"_25":10},"user",{"_7":8,"_9":10,"_11":10,"_12":-5,"_13":-5,"_14":15,"_16":-5},"roles",[],"isAuthenticated",false,"isPremium","planName","subscriptionStatus","featureFlags",{},"insightsBudget","isDevelopmentHost","userPreferences",{},"recaptchaSiteKey","6LcvOJcUAAAAAHsB-gPGfGktcRlKpH7OTIU_dMTD","isImpersonating","impersonation","affiliateStatus","isFreedomPortal","routes/v2/article/layout",{"_28":29,"_30":31},"notFound",true,"relatedArticles",[32,76,88,99],{"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":46,"_47":48,"_49":50,"_51":52,"_53":54,"_55":56,"_57":58,"_59":60,"_61":62,"_63":64,"_65":66,"_67":68,"_69":70,"_71":72,"_73":74,"_75":74},"mediaId",6339257,"mediaKeyId","2262293-9720b953ef8d4ed8a88892e4f7e82bc8","parentId",2262293,"title","Votes at a glance: Committee actions on bills heard Feb. 19, 2025","audioSeconds",125,"startMs",2744000,"endMs",2869000,"viewUrl","/Search/View?dp=1&key=2262293-9720b953ef8d4ed8a88892e4f7e82bc8&start=2744&end=2869","thumbnailUrl","https://assets.pipeline.soar.com/2262293-9720b953ef8d4ed8a88892e4f7e82bc8/thumbnail_2744000.jpg","articleUrl","/articles/6339257/Kansas/Votes-at-a-glance-Committee-actions-on-bills-heard-Feb-19-2025","mediaUrl","https://secure.pipeline.soar.com/6339257-24723cf226d57bb6548d4bf4d75db0dd/orig.mp4?Expires=1775849895&Signature=DZVqqtKwMwuRJY3RSnLQwZmotP7P74zMTivkf4bi-ZkJLb3FA7o1fh35Zj~Yptobpnt~~uLWPQghy2aW0YlhKytR5iVVcvEHMxBFhkFblkPwBLoRYK0wctCjc9cJgDEaoOvLs6igY6t~wgCfBr45MlM6GV01GERIEKrLDaOV6dp0cNI9uujOso3siG23Px2YzZTLfQgi3ZI1hVBM5jpX85ol4UwJKCJN2V2qvkBbry51AbR0giJ35MMb7nYhUXNK4ecQmyYLzhu~27YyP1XGeL4EaimGLwq6cXjyjRHQsnoqOPK9QdItDUU9gYTZDISaxYytvFAaMdf~CZDvGMpZrw__&Key-Pair-Id=KUT5TJCACFTXG","author","KS Legislature","date","2025-02-11T00:00:00Z","article","The Committee on House Health and Human Services recorded the following formal committee actions during the session:

House Bill 2039: Motion to pass out favorably moved by Representative Beeler and seconded by Representative Ellis. Committee members approved the motion by voice vote. The transcript does not record an individual yea/nay tally.

House Bill 2170: Motion to pass out favorably moved by Representative Weichel and seconded by Representative Bergquist. Committee members approved the motion by voice vote; an individual yea/nay tally was not recorded in the transcript.

Notes: Both actions were approved by voice vote during the committee’s work session; the transcript records the motions, seconders and the chair’s announcement that the motions carried, but it does not include roll‑call vote counts.","mediaType","Video","parentTitle","House Committee on Health and Human Services 02/11/2025","oneSentenceSummary","During the session the Committee on House Health and Human Services passed two bills by voice vote and worked others; below are motions and outcomes recorded in the transcript.","taxTitle","Committee on House Health and Human Services, Standing, HOUSE OF REPRESENTATIVES, Committees, Legislative, Kansas","taxId",18811,"location","Kansas","headline","","shortSummary",{"_33":77,"_35":36,"_37":38,"_39":78,"_41":79,"_43":80,"_45":81,"_47":82,"_49":83,"_51":84,"_53":85,"_55":56,"_57":58,"_59":86,"_61":62,"_63":64,"_65":87,"_67":68,"_69":70,"_71":72,"_73":74,"_75":74},6339262,"Committee hears bill to create $4 million annual grant fund for naloxone for law enforcement",1063,1631000,2694000,"/Search/View?dp=1&key=2262293-9720b953ef8d4ed8a88892e4f7e82bc8&start=1631&end=2694","https://assets.pipeline.soar.com/2262293-9720b953ef8d4ed8a88892e4f7e82bc8/thumbnail_1631000.jpg","/articles/6339262/Kansas/Committee-hears-bill-to-create-4-million-annual-grant-fund-for-naloxone-for-law-enforcement","https://secure.pipeline.soar.com/6339262-2a5cddf33792be2f70182062b7dcf2a8/orig.mp4?Expires=1775849895&Signature=FRBuRhnCuusdwVIQLn0pI0Lu3YSc-Zgi44bSEE~-fOLurm3x4rswQhyJ7ZOBCns4E3klZO6fl-fNTclUGI0Su4L3omzBp7Xjbh2eivis0n~k2Tocujxq-C8DB-J9ZniaBh1VkN4tYeZ0FsVq~FtQLwXTgKsuQV0osLSrKgMuwo3tc85jBuv1lsU9vm2-bCfBewUStJlJajcpmvg7aFH7epoqT6KrKAzH8GXPRy3BwdZs2KbMzjJTpsIREX1c6Szz3VXTtJ2doAilumb-looOJ-o7GTnNFN~sjNzdg8zcc3UsV8mwPFIx1Aw0rsN2QYE4KYQ5I836Lwkb5G4fkr8xPQ__&Key-Pair-Id=KUT5TJCACFTXG","The Committee on House Health and Human Services heard proponent testimony on House Bill 2159, which would establish the Emergency Opioid Antagonist Assistance Grant Fund to provide emergency opioid antagonists to law enforcement agencies and remove law enforcement from the state Board of Pharmacy’s statewide opioid antagonist protocol.

Carly, committee staff, walked members through the bill’s major points: the fund would be established in the state treasury and administered by the attorney general; small agencies would receive priority; only agencies that adopt a policy requiring administration of an emergency opioid antagonist would be eligible for grants; and beginning July 1, 2025, the director of accounts would transfer $4,000,000 annually from the state general fund to the grant fund.

Ed Klump, representing the Kansas Sheriffs Association, Kansas Association of Chiefs of Police and Kansas Peace Officers Association, testified in support. He told the committee the fund would help small and rural agencies that currently bear the cost of purchasing naloxone, and he urged removal of a statutory requirement that law enforcement agencies have a medical director for naloxone procurement. “About a half of the agencies in Kansas have 10 or fewer officers, about a third of them have 5 or fewer officers,” Klump said, explaining why the medical‑director requirement imposes costs and operational hurdles for small agencies.

Klump said existing statute retains liability protections for officers who in good faith administer an opioid antagonist and that the bill would preserve those protections. The witness also said grant funding historically has been available through other sources but that gaps remain for agencies that must purchase naloxone out of operating budgets.

Two family members spoke in support and described personal loss. Jennifer Ebert, identifying herself as a grieving mother, described the September 2021 death of her 21‑year‑old son from fentanyl poisoning and said the responding officer did not carry naloxone. “Jason didn’t have to die. If naloxone had been available, he might still be here today,” Ebert said, urging passage of HB 2159. Another witness, Amber, described the 2023 death of her daughter and urged lawmakers to “please support this bill” to give officers lifesaving tools.

During questioning, committee members asked about the bill’s relationship to prior measures allowing EMS to carry and leave naloxone, the fiscal note and the quantity and cost of doses. Klump said he did not have current per‑dose pricing but recalled naloxone was previously about $50–$60 per dose when it required a prescription; he said pricing has changed since naloxone became available over the counter. Carly confirmed the bill calls for a $4,000,000 annual transfer from the general fund beginning July 1, 2025.

The bill’s text also removes law enforcement from the statutory definition of first responder and specifies that a first responder agency does not include any law enforcement agency. The record includes proponent testimony and neutral written testimony from the Kansas State Board of Pharmacy; committee members did not report a floor vote on HB 2159 during the session recorded in the transcript.

(Ending) Committee members closed the hearing after proponent and personal testimony and did not take a formal committee vote on the bill during this session.","House Bill 2159 would create an Emergency Opioid Antagonist Assistance Grant Fund, administered by the attorney general, to help law enforcement agencies purchase naloxone; the bill would also remove law enforcement from the Board of Pharmacy's statewide opioid antagonist protocol and preserve liability protections for officers.",{"_33":89,"_35":36,"_37":38,"_39":90,"_41":91,"_43":92,"_45":92,"_47":93,"_49":94,"_51":95,"_53":96,"_55":56,"_57":58,"_59":97,"_61":62,"_63":64,"_65":98,"_67":68,"_69":70,"_71":72,"_73":74,"_75":74},6339267,"Committee hears bill to exempt FDA‑approved crystalline polymorph psilocybin from Kansas Schedule I",0,2155000,"/Search/View?dp=1&key=2262293-9720b953ef8d4ed8a88892e4f7e82bc8&start=2155&end=2155","https://assets.pipeline.soar.com/2262293-9720b953ef8d4ed8a88892e4f7e82bc8/thumbnail_2155000.jpg","/articles/6339267/Kansas/Committee-hears-bill-to-exempt-FDAapproved-crystalline-polymorph-psilocybin-from-Kansas-Schedule-I","https://secure.pipeline.soar.com/6339267-658f4aa9f4c6bb3fb9fd985f14923bb6/orig.mp4?Expires=1775849896&Signature=a45aAlz-bUS96yQM7WWHE-~Ef3~lzJnWFc8U3hVrdW0YR4a53u9UvaJ1AcIXgevY26cUEMoH3pdI2fhsMmYbcXfJsU~2BxDDD6hZDeIraremdC1EE2hWs0pDD8qiz33ROkMLpuNcHJzfcQCnqBVZbBGY~RkPXLfvDxBqQHvR~wltPgVI3lbUztesTQyW4PCqTGrQY7~atLUpcxLLZ7H8EsUZO~JnEddZKfEB0sKRwM-3X2DZUUUjhR7LTHxE2p5cc0V42PbFaWlGMgLzGlXCMlfAkjtoDGXTTC125eR0GPWyJGb62nFhbpfUJJAuRkaPeo5Xnxx8iYKNHCS2FpWqig__&Key-Pair-Id=KUT5TJCACFTXG","The Committee on House Health and Human Services held a hearing on House Bill 2218, a bill that would amend the Kansas Uniform Controlled Substances Act to exclude an FDA‑approved pharmaceutical composition of crystalline polymorph psilocybin from the Schedule I definition and to add any such FDA‑approved product to Schedule IV after federal approvals and state certification.

Carly, committee staff, summarized the bill’s sections and the procedural trigger: the bill would take effect after an FDA approval of a pharmaceutical crystalline polymorph psilocybin product, followed by certification by the attorney general and publication by the secretary of state. Carly told the committee the text amends KSA 65-41-01 (definitions) and KSA 65-41-11 (schedules).

Tess Betler, senior manager of advocacy and state government policy at Compass Pathways, testified in support. “This bill does not decriminalize or legalize psilocybin or any other psychedelic substance, nor does this bill allow access to drugs that have not been FDA approved,” Betler said. She told members the change is intended to allow rapid state-level access to a prescription product if and when the Food and Drug Administration approves a crystalline polymorph psilocybin formulation and the Drug Enforcement Administration reschedules it.

Betler said the company’s product is a 25‑milligram capsule that would be administered in a doctor’s office under the anticipated FDA risk‑management plan. She emphasized the bill would have no effect unless the FDA actually approves a product. “If the FDA does not approve it, then nothing happens in Kansas,” Betler said.

Members asked about clinical trials, manufacturing and timing. Betler confirmed the formulation being discussed is synthesized rather than harvested from mushrooms and said clinical trials are ongoing; she told the committee the sponsor does not expect trials to finish until 2026. Representative Bryce and others asked about the mechanism of action; Betler described research suggesting psilocybin increases “neuroplasticity” and creates new connections in the brain, though she acknowledged the mechanism is not fully understood.

Representative Sanverise asked why the bill is being proposed before federal approvals; Betler said the intent is to have statutory language in place so that patients could access an FDA‑approved, DEA‑rescheduled product promptly. Committee members raised concerns about whether state action could affect people who cultivate or possess natural mushrooms; Betler said the bill was intended only to amend the Uniform Controlled Substances Act definitions and not to alter enforcement of natural‑product prohibitions.

No committee vote was recorded on House Bill 2218 during the hearing. The record includes written opposition from James Davis and neutral written testimony from Alexandra Blasey of the Kansas State Board of Pharmacy.

(Ending) The committee closed the hearing after testimony and questions; members did not take a formal vote on the bill during this session.","Witnesses and committee members discussed House Bill 2218, which would amend Kansas law to exclude FDA‑approved pharmaceutical crystalline polymorph psilocybin from the Schedule I controlled substances list and add such FDA‑approved products to Schedule IV once federal approvals and state certification occur.",{"_33":100,"_35":36,"_37":38,"_39":101,"_41":102,"_43":103,"_45":46,"_47":104,"_49":105,"_51":106,"_53":107,"_55":56,"_57":58,"_59":108,"_61":62,"_63":64,"_65":109,"_67":68,"_69":70,"_71":72,"_73":74,"_75":74},6339272,"House committee passes bill to designate first full week of February as Kansas Burn Awareness Week",2213,656000,"/Search/View?dp=1&key=2262293-9720b953ef8d4ed8a88892e4f7e82bc8&start=656&end=2869","https://assets.pipeline.soar.com/2262293-9720b953ef8d4ed8a88892e4f7e82bc8/thumbnail_656000.jpg","/articles/6339272/Kansas/House-committee-passes-bill-to-designate-first-full-week-of-February-as-Kansas-Burn-Awareness-Week","https://secure.pipeline.soar.com/6339272-57af251b18b35302370aa7ca5cfc5d30/orig.mp4?Expires=1775849896&Signature=D86LMasDguxAjkZw6dIYqg8kLU64XyI9YUii5ReZzwP-uTga8GO5~Vf9V5hQHuxtpXtDmTsGkxqYCuLCLwfbqrUqaT41PAF7lf-NUhpJf5WwO7tWYeKtQOixLMcnzHsiTzBLW2auMz2~thkDutZsjhGNvODmgUjrwqUuSX7er6q6iTX9AmO8nw3E2pLVkMopQJgFOm8GILaUJebmiTW5hmFM6aTi1s3hfLWW-e9qgkiY8ywxcZ2RcJAVKPK0mjQ8YJ1bR8lIwWiFCbaxFY6P-je-6PPWB0xd0ManJRrc1cxLVOBlN8rZGsXiNobnCeuQVbZIgKc-lF8b7cbxlmNN3w__&Key-Pair-Id=KUT5TJCACFTXG","The Committee on House Health and Human Services passed House Bill 2170, which would designate the first full week of February each year as Kansas Burn Awareness Week and take effect July 1, 2025, after publication in the statute book.

The bill’s sponsor and proponent witnesses said the change would codify the American Burn Association’s national observance in state law, honor people who have died or been injured in burn incidents, and promote public education about prevention and treatment.

Carly, a committee staff member, summarized the bill’s language and effective date and said the bill “would take effect on 07/01/2025 after publication in the statute book.” Dr. Julia, identified in committee testimony as the burn director representing the Burnett Burn Center at the University of Kansas Health System and the Ascension Via Christi Regional Burn Center, urged approval and provided national and state statistics. “Burns are some of the most devastating of all medical emergencies,” Dr. Julia said, noting that “over 400,000 people seek care for burn injuries every year” in the United States and that “of those who seek care, over 3,000 will die in this country each year.” She added that advances in care have produced a survival rate greater than 96 percent for patients admitted to burn units.

Dr. Julia said burn survivors often require prolonged, multidisciplinary care. She told the committee the proposed week would both “honor those who have lost their lives or suffered severe burn injuries” and “educate the public on effective preventive measures to avoid accidental burn injuries or fatalities.” The witness said the centers she represented strongly support the bill and requested a favorable report from the committee.

During committee consideration, Representative Weichel moved to pass the bill out favorably; Representative Bergquist seconded. The committee approved the motion by voice vote; a roll-call tally was not recorded in the transcript.

The bill’s text specifies the observance and cross-references national recognition; any administrative steps required for implementation were not detailed in testimony. The bill would become effective July 1, 2025, contingent on publication in the statute book.

Committee action: motion carried by voice vote; individual yea/nay tallies were not specified on the record.

(Ending) The committee’s vote sends House Bill 2170 to the next legislative stage for further consideration by the full House.","The Committee on House Health and Human Services voted to pass House Bill 2170, which would designate the first full week of February each year as Kansas Burn Awareness Week to honor victims, raise prevention awareness and align with national observance.","actionData","errors"]

Article not found

Votes at a glance: Committee actions on bills heard Feb. 19, 2025

Committee hears bill to create $4 million annual grant fund for naloxone for law enforcement

Committee hears bill to exempt FDA‑approved crystalline polymorph psilocybin from Kansas Schedule I

House committee passes bill to designate first full week of February as Kansas Burn Awareness Week